Notified Body Fees Must Be Readily Accessible, Fair And Transparent, MDCG States
The latest EU guidance document seems full of good sense in determining how notified bodies should communicate their fees, helping industry compare prices. But it does not address actual fee levels themselves.
You may also be interested in...
The European Commission’s proposal to extend transition timelines for legacy devices in the context of the Medical Device Regulation is already on the move. There are still questions, however, about whether a fast-track adoption is in the best interests of the medtech sector.
A review of expert panel opinions related to high-risk medical devices shows no challenges yet by notified bodies to their findings.
There had been handful of warning signals against well-known notified bodies designated against the MDR. Why were they there and why have they just been removed?